Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Exploiting the therapeutic implications of KRAS inhibition on tumor immunity
Míriam Molina‐Arcas, Julian Downward
Cancer Cell (2024) Vol. 42, Iss. 3, pp. 338-357
Open Access | Times Cited: 46

Showing 1-25 of 46 citing articles:

Targeting KRAS: from metabolic regulation to cancer treatment
Yanyan Shi, Huiling Zheng, Tianzhen Wang, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 3
Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer
Caicun Zhou, Chongyang Li, Libo Luo, et al.
Cancer Cell (2024) Vol. 42, Iss. 7, pp. 1286-1300.e8
Closed Access | Times Cited: 11
MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer
Sílvia Casacuberta‐Serra, Íñigo González-Larreategui, Daniel Capitán-Leo, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 8
Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial
Yuankai Shi, Jian Fang, Ligang Xing, et al.
Nature Medicine (2025)
Closed Access | Times Cited: 1
Real-World outcomes of Non-Small cell lung cancer patients harbouring KRAS G12C and KRAS G12D mutations
Adel Shahnam, Alexander Davis, Lauren Brown, et al.
Lung Cancer (2025) Vol. 201, pp. 108421-108421
Closed Access | Times Cited: 1
Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment
Szu-Aun Long, Amber M. Amparo, Grace Goodhart, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 5
The continually evolving landscape of novel therapies in oncogene-driven advanced non-small-cell lung cancer
Barbara Melosky, Rosalyn A. Juergens, Shantanu Banerji, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
Current Strategies and Future Dimensions in the Development of KRAS Inhibitors for Targeted Anticancer Therapy
Laura D'Alessio‐Sands, Joshua Gaynier, Victoria Michel‐Milian, et al.
Drug Development Research (2025) Vol. 86, Iss. 1
Closed Access
Distinct molecular and clinical features of specific variants of KRAS codon 12 in pancreatic adenocarcinoma
Bach Ardalan, Aaron Ciner, Yasmine Baca, et al.
Clinical Cancer Research (2025)
Open Access
Cancer Vaccines and Beyond: The Transformative Role of Nanotechnology in Immunotherapy
Violeta Delgado-Almenta, José L. Blaya-Cánovas, Jesús Calahorra, et al.
Pharmaceutics (2025) Vol. 17, Iss. 2, pp. 216-216
Open Access
STAT3 Inhibition Prevents Adaptive Resistance and Augments NK Cell Cytotoxicity to KRASG12C Inhibitors in Nonsmall Cell Lung Cancer
Zehao Pan, Yuxian Qian, Yajing Wang, et al.
Cancer Science (2025)
Open Access
KRASG12D-driven pentose phosphate pathway remodeling imparts a targetable vulnerability synergizing with MRTX1133 for durable remissions in PDAC
Xiangyan Jiang, Tao Wang, Bin Zhao, et al.
Cell Reports Medicine (2025) Vol. 6, Iss. 2, pp. 101966-101966
Open Access
Genome-wide CRISPR screening identifies PHF8 as an effective therapeutic target for KRAS- or BRAF-mutant colorectal cancers
Zhao Liu, Yiqi Li, Simeng Wang, et al.
Journal of Experimental & Clinical Cancer Research (2025) Vol. 44, Iss. 1
Open Access
Resistance to Immunotherapy in Non-small Cell Lung Cancer: Unraveling Causes, Developing Effective Strategies, and Exploring Potential Breakthroughs
Shuang Dong, Xiaoyu Li, Qing Huang, et al.
Drug Resistance Updates (2025) Vol. 81, pp. 101215-101215
Closed Access
Small molecules for Kirsten rat sarcoma viral oncogene homolog mutant cancers: Past, present, and future
Peiliang Dong, Jiating Ni, Xinyue Zheng, et al.
European Journal of Pharmacology (2025), pp. 177428-177428
Closed Access
Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial
Kohei Shitara, Yelena Y. Janjigian, Jaffer A. Ajani, et al.
Nature Medicine (2025)
Open Access
ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma
Dhana Sekhar Reddy Bandi, Ganji Purnachandra Nagaraju, Sujith Sarvesh, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access
New exploration of KRASG12D inhibitors and the mechanisms of resistance
Yinghong Li, Junfeng Zhao, Yintao Li
Experimental Hematology and Oncology (2025) Vol. 14, Iss. 1
Open Access
Advocating for change—Integration of efforts across the drug discovery and development continuum
Timothy P. Heffernan, Giulio Draetta
Cancer Cell (2025)
Closed Access
Advances in the treatment of KRASG12C mutant non–small cell lung cancer
Khvaramze Shaverdashvili, Timothy F. Burns
Cancer (2025) Vol. 131, Iss. S1
Open Access
Mechanisms of resistance to KRASG12C inhibitors in KRASG12C-mutated non-small cell lung cancer
Ali Chour, Anne‐Claire Toffart, E. Berton, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 3
Resistance to KRAS inhibition in advanced non-small cell lung cancer
Katherina Bernadette Sreter, Maria Joana Catarata, Maximilian von Laffert, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 2
Leveraging Cancer Phenotypic Plasticity for Novel Treatment Strategies
Sravani Ramisetty, Ayalur Raghu Subbalakshmi, Siddhika Pareek, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 11, pp. 3337-3337
Open Access | Times Cited: 2
Novel Heteroaryl Fluoroalkenes as DGK Inhibitors for Treating Cancer, Particularly Metastatic Melanoma
Ram W. Sabnis
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 9, pp. 1433-1434
Open Access | Times Cited: 2
Breakthrough in RAS targeting with pan-RAS(ON) inhibitors RMC-7977 and RMC-6236
Panagiotis Filis, Dimitrios Salgkamis, Alexios Matikas, et al.
Drug Discovery Today (2024), pp. 104250-104250
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top